The Index
400 dossiers · 1 need attention
A research screener for every company we cover. Search a name or ticker, then sort and triage dossiers by coverage freshness, our conviction and trading relevance.
Bullish3 names· avg TR 14 | ||||||||
| The market prices Micron as a peak-cycle memory-cyclical (~9–10× forward) while it becomes a structural HBM oligopolist on multi-year contracts — a re-rating bet, not an earnings bet, with peak-cycle entry risk. BULLISH / MEDIUM / 1Y. | BullishMed | 11 | ||||||
| Captures the LARGEST slice of the HBM scarcity rent (~62% share, ~2/3 of NVIDIA's HBM4, 72% op margin, ~61% ROE) yet is valued like a Korean memory-cyclical (~6–9× forward) — and management's own $14B US listing is an explicit re-rating bet. Best HBM rent-capture in the cluster. BULLISH / MEDIUM-HIGH / 1Y. | BullishMed | |||||||
T | The chokepoint that captures the foundry + CoWoS-packaging rent for the ENTIRE AI complex (NVIDIA, AMD, Broadcom, Apple all depend on it), trading at ~22× forward — BELOW every customer it supplies — with the only real risk exogenous (Taiwan geopolitics, the source of the discount). The cleanest, highest-quality, lowest-multiple way to own AI infrastructure. BULLISH / HIGH / 1Y+. | BullishHigh | ||||||
Watching1 name· avg TR 11 | ||||||||
| The most dangerous competitor bulls underestimate — the named beneficiary of NVIDIA's own inference-share vulnerability, growing AI +143% — but priced at a PREMIUM to NVIDIA (45× vs 30× EV/EBITDA) on one-third the ROE, with lower earnings quality (acquisition-amortization add-backs, $64B debt) and the same hyperscaler concentration. The most expensive, lowest-quality way to play the custom-silicon thesis. NEUTRAL / WATCHING / MEDIUM. | ||||||||
No call49 names· avg TR 5· 1 need attention | ||||||||
| A genuine top-4 global optical-component IDM riding the AI interconnect wave — but it is the low-margin generalist (~8% net) trading at a specialist multiple after a 5x run, with consensus targets implying ~55% downside. Real franchise, priced for a margin structure it has never earned. | — | |||||||
| 11 |
| The only Western "mine-to-magnet" pure-play levered specifically to HEAVY rare earths (Dy/Tb) — whose ex-China prices have ~doubled in 2026 (Dy ~US$930/kg, Tb ~US$4,028/kg) — via China's own low-cost ionic-clay geology; but it is a pre-revenue developer that has already re-rated ~5x to a ~CA$1.1B cap, owns a Chilean asset 99% of the local community voted against, faces MP Materials commissioning its own US HREE separation by mid-2026, and must fund a >US$1.5B integrated build off a ~US$40M cash balance with no binding offtake. Asymmetric optionality, not yet a position. | — | 8 |
| ALB is a high-quality, low-cost lithium asset wearing the price tag of a leveraged call option on the lithium spot price — own the resources, not the P&L; the stock is the commodity in a cyclical costume. | — | 0 |
| A binary supply-shock proxy — the only Western-aligned tungsten scale producer ramping into a 550%-China-driven price spike, but priced at ~150x trailing sales on a single-mine ramp; own the commodity thesis, not this multiple — a quarter of Sangdong slippage or one China de-escalation re-rates it 40%+. | — | 8 |
| The highest-grade tin mine on earth, throwing off >$600M annualised EBITDA at a 6.7x P/E — and it sits 180km from an active M23 front line in the eastern DRC, now 56%-owned by Abu Dhabi. The discount is the country, not the company; you are paid ~6.5% to wait, but a single security headline can halve it overnight. | — | 8 |
| A three-engine critical-materials conglomerate whose 2025–26 earnings are flattered by a transient antimony windfall while its real long-duration call options (European LiOH at Bitterfeld, spent-catalyst vanadium recycling, the Saudi Supercenter) are still pre-cash-flow — own the structural story, but underwrite the cycle, not the print. | — | 8 |
| A copper pure-play being born inside an iron-ore company — own the re-rate that completes when Anglo Teck closes, not the diversified miner that's disappearing. | — | 8 |
| A best-in-class, Luksic-controlled Chilean copper pure-play priced for the 30% volume ramp it has not yet delivered — own the asset, not this multiple; the entry is a copper-price dip or a Centinela-2 commissioning wobble, not 14x EV/EBITDA on a name that just missed guidance again. | — | 8 |
| A 38-year, $1.7B-NPV NdPr asset that the equity market is pricing as a serial dilution machine — the call is on financing-close + China's price floor, not the ore body. WATCHING into FID-completion; the project is fundable, the share count is the bear case. | — | 8 |
| A self-help margin re-rating priced as a doomed smelter — the $0 TC/RC tape masks that Aurubis already earns more from downstream premiums, recycling and a finished $1.7B capex cycle than from the concentrate spread the bears fixate on; watching, not yet a buy, because the metal-price tailwind that lifted FY25/26 guidance twice is the same lever that breaks on a copper pullback. | — | 8 |
| The base-editing platform with the cleanest in-vivo clinical proof-of-concept yet (BEAM-302 corrected a disease-causing mutation in living patients) and a near-term commercial shot (risto-cel BLA by YE26) — a genuine BULLISH-but-binary genomics name where the science de-risked faster than the commercial model. | — | 0 |
| A best-in-class integrated Nordic miner-smelter whose precious-metal-rich, e-scrap-fed smelter chain is the rare structural winner of the negative-TC era — but at ~21x P/E and a price above the average analyst target, the stock already prices the gold-silver windfall, not the smelter-margin reset risk and post-fire/post-acquisition execution debt. | — | 8 |
| The world's lowest-cost EV/battery manufacturer is now margin-bleeding in a brutal domestic price war it helped start; the entire bull case has migrated to a high-margin export ramp that tariffs and a Brazil/Hungary regulatory cloud are built to throttle — cheap on forward P/E only if you trust earnings that GMT says are flattered by ~¥300B of supply-chain-financed hidden debt. | — | 0 |
| World's #2 nickel reserve at first-quartile cost with state backing — but a US$2.5bn funding gap on a ~C$400m shell means the entire bet is binary on the 2026 financing close, not the geology. | — | 8 |
| A Bitmain/Antalpha-controlled reverse-merger shell wearing a Bitcoin-miner costume and now an AI-compute costume — high-cost fleet, ~50% related-party voting control, a NYSE sub-$1 delisting clock, and a balance sheet half-built on Antalpha loans; avoid the equity, watch only as a Bitmain-proxy / forced-restructuring special situation. | — | 0 |
| A leveraged, pure-play Americas copper call trading at a mid-tier P/NAV discount — own it for the deficit and the MV-Optimized/Santo Domingo growth stack, but the entry price is now a bet that record copper holds, not that the assets are cheap. | — | 8 |
| Real wafer-scale inference moat priced at ~92x sales on demand that is circular (OpenAI is customer + lender + shareholder) and concentrated — the IPO swapped UAE concentration for OpenAI concentration. WATCHING, bear-leaning on valuation. | — | 1 |
| The world's largest rare-earth producer is a state policy instrument, not a shareholder vehicle — at P/E ~66 / ~$25B cap on ~7% ROE you are paying a growth multiple for a margin that its own parent (Baogang) taxes away one concentrate hike at a time. Own the NdPr theme through a price-taker, not this price-maker-that-isn't. | — | 8 |
| World's #1 cobalt + a top-tier DRC copper grower trading at a deep state-owned/jurisdiction discount (~4-9x P/E vs 12-22x peers) — the value gap is the thesis; the DRC quota regime and Beijing's hand on the till are the reasons it persists. | — | 8 |
C Coherent Corpcatalyst in 43d | An II-VI/Coherent merger debt-mule reborn as the picks-and-shovels supplier of the AI-optics supercycle — backed out to 2028, Nvidia-anchored, and de-risking the balance sheet — but priced at ~49x forward EPS that already embeds flawless CPO execution it has not yet proven. | — | 0 |
| A de-risked computational-discovery option on AstraZeneca's rilvegostomig — the last surviving TIGIT bet — wrapped around a $135M cash shell and a binary 2027 ovarian readout; you are buying the royalty stream and the platform, not COM701. | — | 0 |
| The best nuclear asset base in America, now bolted to a gas fleet and priced as an AI-power call — at ~26x forward the upside is no longer in the price for free, and the Dec-2025 FERC co-location order is the binary the bulls are underweighting. | — | 0 |
| The cheapest dominant company in the world — a 40%-share, 27%-ROE compounder priced at ~22x because it carries a Chinese-passport discount and a US-blacklist overhang the market refuses to underwrite away; bullish, but the re-rate needs a geopolitical thaw that may never come. | — | 0 |
| A wide-moat seed/chem duopolist priced for steady compounding, sitting on a triple inflection — royalty flip to net out-licensor, the Bayer settlement unlocking corn/cotton licensing, and a 2H26 split that hands the clean-growth Seed business to SpinCo and dumps every legacy liability on Crop-Protection-Co; own the seeds, scrutinize the chem. | — | 0 |
| A genuinely strategic Western heavy-rare-earth asset wrapped in a serial-promoter, pre-revenue, dilution-machine equity — the deposit is real, the metallurgy and the 2029 cash-flow date are not yet, and the stock already prices a permitting+offtake fairy-tale at ~$1.5B with $0 revenue; WATCHING, would only own on a proven-metallurgy or fully-funded BFS catalyst. | — | 8 |
| Best-in-class ag-equipment compounder at the bottom of a brutal large-ag cycle, already re-rated to ~32x on a trough-earnings recovery — the moat and the precision-ag option are real, but the price has front-run the recovery, so this is a high-quality WATCH, not a fresh entry. | — | 0 |
| The best operating asset in pharma trading at a price that already imputes a $150B+ obesity TAM — own it on the franchise and the orforglipron/retatrutide optionality, but size for a multiple that compresses from ~30x forward as the price war and TAM-skeptic camp grind on the narrative. | — | 1 |
| A 20-year serial cash-burner with a real PLC fab and a going-concern stamp, re-skinned as a CPO/AI-optics pure-play — the FR8 order is genuine but the balance sheet, not the technology, decides this stock. | — | 8 |
| The cheapest, highest-margin way to own the 800G/1.6T AI-interconnect ramp — but it is a no-CIK Chinese A-share whose 47% margins, 96% offshore revenue and ~52x P/E all rest on a Broadcom-DSP / Lumentum-EML leash it doesn't own and a hyperscaler order book it can't diversify. | — | 8 |
| A real lunar/launch franchise wrapped in a serial-failure rocket, a money-furnace P&L, and a ~32x-sales price — the Golden Dome/SciTec defense pivot is the only thing that justifies the multiple, and Eclipse first-flight is the binary that settles it. | — | 0 |
| A near-death epiwafer monopolist just got bought out of bankruptcy by its own customer — own the InP photonics call, not the company; the AI-optical TAM is real but the float is a recovery option on a chronically capex-starved, margin-thin foundry whose two largest customers now sit on its board. | — | 8 |
| The toll-booth on chip yield — a ~58%-share process-control near-monopoly whose revenue scales with chip *complexity*, not wafer volume, so it compounds even through capex air-pockets; the only real debate is the price you pay, not the quality of the business. | — | 0 |
| A counter-cyclical compounder mid-re-rate — the destocking trough is behind it and the FY26 earnings snapback is real, but at ~¥2,900 / +81% off the lows the easy money is made; tariffs and a structurally weak NA ag market cap the upside from here. | — | 8 |
| A great battery operator strapped to a collapsing demand curve and a U.S. subsidy that is its only profit — the franchise is real, but the 2027-2032 order book just lost ~$9B of contracted Ford/FBPS volume and AMPC repeal is an existential tail risk; WATCHING, not buying, until the ESS pivot proves it can replace lost auto cells at a real margin. | — | 8 |
| Metsera is no longer an investable equity — Pfizer closed the buyout at $65.60 cash on 13-Nov-2025; the only live instrument is the non-transferable CVR (up to $20.65/sh on three obesity-approval milestones), realistically worth a fraction of par, and the durable trade is the read-through to PFE/NVO/LLY and the amylin thesis, not MTSR. | — | 8 |
| A fallen-angel GLP-1 franchise trading at a generic-pharma multiple on a still-growing branded book — but the de-rating is a verdict on durability (Lilly's tirzepatide is structurally better, semaglutide's US patent cliff is 2031–32), and the cheapness is only a buy if the oral-Wegovy ramp and the amycretin pipeline can defend share before exclusivity breaks. | — | 0 |
| World's #1 potash producer + #1 ag-retailer, mid-cycle and cheap (~11x fwd P/E, 1.8x levered), self-help via portfolio simplification — a high-quality cyclical you buy near trough, not a compounder; BULLISH-tactical, not structural. | — | 8 |
| A genuine top-tier Chinese optics merchant (top-3 passive, #9 global components, real InP/SiPh chip + 1.6T/CPO roadmap) trapped behind a 6-year private wrapper — the only tradeable expression today is the STAR-Market IPO it has been "about to file" since 2023; not investable until the S-1 (招股书) lands, and the coverage ticker 0877.HK is the WRONG company. | — | 8 |
| A real long-read/native-modification monopoly inside a structurally hard razor-and-blade model — but the market has stopped paying for "deep tech that takes 10 years"; down 73% from IPO, near 52-week lows, it is a show-me story where 2027 EBITDA breakeven (twice-pushed) is the entire thesis, and the new ex-Danaher CEO either professionalizes the commercial engine or the optionality stays un-priced. | — | 8 |
| A premium-cell incumbent being squeezed from below by Chinese LFP scale and above by its own Tesla over-concentration — but the unit now has a genuine second engine (data-center backup, ~80% share) that the parent's 46x-PER stock does not yet price as a battery turnaround. | — | 8 |
| A genuinely great company and a genuinely terrible price — the only Western full-stack launch+satellite pure-play, compounding at ~50%, but trading at ~64x EV/sales with the entire Neutron thesis still un-flown. Own the business, fade the multiple. | — | 0 |
| The cheapest way to own the memory supercycle — a $63B-net-cash colossus that just clawed back into Nvidia's HBM4 supply chain at ~7x forward earnings, but the market's discount is a verdict on memory cyclicality and Samsung's execution, not a mistake. Bullish on the re-rate; the kill-switch is a 2027 oversupply that turns peak earnings into the top tick. | — | 8 |
| A loss-making #9 EV-cell laggard re-rating on an ESS/data-center pivot the market is pricing as a turnaround — the call is whether US grid-storage demand and 2027 solid-state outrun Chinese LFP deflation before the balance sheet (rights issue + Display-stake sale) runs out of runway. | — | 8 |
| A levered, sub-NAV Ethereum proxy run by the best operators in the trade — own the discount-closing buyback, not the "treasury premium" that already died; the bet is ETH plus a 0.83x→1.0x mNAV mean-reversion, fighting a 95% drawdown and a structurally bigger rival. | — | 0 |
| A genuine launch-and-connectivity monopoly wrapped inside an unprofitable $2T+ aspiration stock — Starlink is the real business, but at ~110x sales the market is paying for Mars, orbital AI data centers, and a $60B Cursor bet that aren't earnings yet. | — | 8 |
| A genuinely differentiated case-handling robotics moat wrapped around an ungovernable accounting-and-concentration core — adverse ICFR opinion + active SEC whistleblower probe + >90% Walmart revenue means the multiple is pricing a clean compounder that the filings say does not yet exist. | — | 0 |
| A profitable EV maker priced as a solved-autonomy robotics company — the car business is shrinking, the GAAP profit prop (reg credits) is going to zero, and the entire ~190x multiple now rents on robotaxi + Optimus execution that is real but years behind the price. | — | 0 |
| A cash-gushing CF monopoly priced for a successful four-engine diversification (pain, renal, gene therapy, diabetes) that is, so far, only one-third proven — own the moat, underwrite the pipeline at a discount. | — | 0 |
| The picks-and-shovels king of the AI buildout — #1 in optical transceivers with >50% of Nvidia's wallet and the lowest forward P/E of any peer — but it is a margin-taker squeezed between US chip suppliers it cannot displace (Broadcom/Marvell DSP, Lumentum/Coherent EML) and Nvidia's own CPO/in-house ambitions, and the price already discounts flawless 1.6T execution. | — | 8 |